How much is Scorpion Therapeutics worth in 2026?

Scorpion Therapeutics has a current valuation of N/A based on their Later Stage VC (Series C) round and secondary market data.

How much funding has Scorpion Therapeutics raised?

Scorpion Therapeutics has raised N/A in total funding across 1 funding rounds.

Scorpion Therapeutics

Drug Discovery

Scorpion Therapeutics valuation and funding history | Last updated: July 16, 2024 | 1 funding rounds

Current Valuation

N/A

As of July 16, 2024

Total Funding Raised

N/A

Across 1 round

Last Round

Later Stage VC (Series C)

$150.0M

Last Funding

Jul 2024

Funding date

Capital Efficiency

N/A

Valuation / Funding

Funding History & Valuation Timeline

Complete history of all funding rounds and valuation milestones

Date	Round	Amount	Post-Valuation	Growth
July 16, 2024	Later Stage VC (Series C)	$150.0M	N/A	-

Valuation Analysis

Current Valuation Metrics

Scorpion Therapeutics is currently valued at N/A as of July 16, 2024.

Track Scorpion Therapeutics Valuation Updates

Get notified when Scorpion Therapeutics raises new funding or valuation changes

Explore More Data

Detailed analysis for Scorpion Therapeutics

Secondary Market Price

Real-time pricing data and trends

Valuation Tracker

Historical valuation changes

Funding History

Complete funding round timeline

Secondary Price History

Historical transaction data

All Investors

Complete list of all investors

View 5 companies free

Create a free account to unlock Scorpion Therapeutics's valuation history, funding rounds, and growth metrics.

No credit card required

What is Scorpion Therapeutics Worth in 2026?

Scorpion Therapeutics is a leading private company in the Drug Discovery sector. Track Scorpion Therapeutics's valuation history, funding timeline, and implied market value from secondary transactions on Premier Alternatives.

How Scorpion Therapeutics Valuation is Determined

Private company valuations like Scorpion Therapeutics's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including revenue growth, market opportunity, competitive positioning, and investor sentiment.